Next Science (ASX:NXS) share price falls despite 'exciting future ahead'

The Next Science Ltd (ASX: NXS) share price slumped today following the company's 2021 AGM presentation. Let's take a closer look.

| More on:
investor looking up as if watching asx share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Next Science Ltd (ASX: NXS) shares were on the slide today after the release of the company's 2021 AGM presentation. By market close, the Next Science share price was trading 2.01% lower at $1.71. This came following gains of almost 5% for the company's shares yesterday.

Next Science is focused on the research, development and commercialisation of technologies that aim to solve issues in human health caused by biofilms. The AGM was mainly focused on the company's BlastX wound-treatment products. Let's dive a little deeper into the presentation.

AGM presentation

Next Science markets itself as "the only company in the world solely dedicated to developing products that resolve biofilm based infections." The company's current focus is its wound-care product, BlastX, which has shown significant promise in accelerating the healing of major chronic wounds that are still before the necrotic stage.

The products work at removing pathogens from wound areas. While the company is still seeking some regulatory approvals in key markets, more than 15,000 patients have been treated using its products.

The Next Science share price was in the red today despite the company reporting "returned revenue to growth" in the fourth quarter of 2020. According to Next Science, Q4 revenue showed 75% growth on the same quarter in 2019. The company has commissioned a sales force of over 200 people in the United States and has capital raised $15 million to fund its product commercialisation.

Management comments

Next Science chair Mark Compton briefly admitted the challenges Next Science has faced in the US. He said:

Next Science is a relatively young company, with an exciting future ahead of it. There were many challenges in 2020, with key ones being the health risks to our staff and their families and the sales and marketing constraints of trying to engage a hospital and healthcare system totally focused on dealing with an all-consuming global pandemic that deeply penetrated the US.

As we look back to such a challenging year, I am pleased to report that much progress has been made at Next Science.

Next Science share price snapshot

Despite today's falls, the Next Science share price has gained almost 30% over the past month. It's also up by around 37% year to date. Over the past year, however, the company's shares have only gained 3.64%. Next Science has a current market capitalisation of around $345 million.

Lucas Radbourne-Pugh has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Nexus Energy Limited. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Sell and buy on red cubes on a digital screen.
Technology Shares

This ASX 200 high-flyer dropped 15%, is it time to jump in?

Analysts remain positive due to the company's strong fundamentals.

Read more »

Focused man entrepreneur with glasses working, looking at laptop screen thinking about something intently while sitting in the office.
Healthcare Shares

Are CSL shares a buy after their heavy decline?

Let's see what one broker is saying about the biotech giant.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Why are Telix Pharmaceuticals shares diving today?

Shares in this up-and-coming drug company are under pressure over law suits filed in the US.

Read more »

A young woman wearing a red and white striped t-shirt puts her hand to her chin and looks sideways as she wonders whether to buy ASX shares
Healthcare Shares

CSL, Sonic, and Sigma Healthcare shares: Buy, hold, or sell?

Analysts share their ratings and opinions on 3 large-cap ASX 200 healthcare stocks.

Read more »

young female doctor with digital tablet looking confused.
Healthcare Shares

Down 38% in a year, are CSL shares now a buy?

A leading investment expert delivers his verdict on CSL shares.

Read more »

A woman holds her hand out under a graphic hologram image of a human brain with brightly lit segments and section points.
Healthcare Shares

This Cochlear-backed ASX aspirant will be targeting an epilepsy market worth north of $1 billion

This company is looking to raise $125 million to help commercialise its epilepsy monitoring technology.

Read more »

Surgeon looking at a monitor in an operating room.
Share Market News

Is the only way up for this ASX small-cap healthcare stock?

Bigger returns could be coming for this ambitious small-cap.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Monash IVF has named a new Managing Director to help right the ship

Monash IVF has named a new leader, but she will not start in the top job for some time.

Read more »